Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/21252

Title:	Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.
Authors:	Serrano, José M González, Iria del Castillo, Silvia Muñiz, Javier Morales, Luis J Moreno, Fernando Jiménez, Rosa Cristóbal Varela, Carmen Graupner, Catherine Talavera, Pedro Curcio, Alejandro Martínez, Paula Guerra, Juan A Alonso-Martín, Joaquín View more
Keywords:	Anthracycline chemotherapy Breast cancer Cardiac biomarkers Diastolic dysfunction View more
Mesh:	Adult Anthracyclines Breast Neoplasms Cardiomyopathies Cohort Studies Diastole Female Humans Incidence Middle Aged Prospective Studies Ultrasonography View more
Decs:	Ultrasonografía Diástole Cardiomiopatías Neoplasias de la Mama Antraciclinas View more
Issue Date:	Aug-2015
Citation:	Oncologist.2015 Aug;(20)8:864-72
Abstract:	Cardiotoxicity represents a major limitation for the use of anthracyclines or trastuzumab in breast cancer patients. Data from longitudinal studies of diastolic dysfunction (DD) in this group of patients are scarce. The objective of the present study was to assess the incidence, evolution, and predictors of DD in patients with breast cancer treated with anthracyclines.
PMID:	26185196
URI:	https://hdl.handle.net/20.500.12530/21252
Rights:	openAccess
Appears in Collections:	Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:

File	Description	Size	Format
PMC4524754.pdf		1.73 MB	Adobe PDF	View/Open